2025-11-15 - Analysis Report
Okay, here's an analysis of Natera Inc. (NTRA) based on the information you provided.  I'll present the data, analyze each section, and then provide a comprehensive summary.

## Natera Inc. (NTRA) Analysis

Natera Inc. is a diagnostics company that focuses on cell-free DNA testing for reproductive health, oncology, and organ health.

### 1. Performance vs. S&P 500 (VOO)

**Numbers:**

*   NTRA Cumulative Return: 110.29%
*   VOO Cumulative Return: 99.28%
*   Spread (NTRA - VOO): 4.5 (Max: 174.8, Min: -88.5, Relative Spread: 35.3)

**Analysis:**

NTRA has outperformed the S&P 500 (VOO) with a cumulative return difference of 4.5%. However, the relative spread of 35.3 indicates that this outperformance is not exceptionally high compared to its historical range against the S&P 500. The stock is trading 35.3% within its historical performance range relative to the S&P 500, suggesting that while it's currently outperforming, the magnitude of this outperformance isn't at its historical peak.

**Alpha/Beta Analysis Table:**

| Year        | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
| ----------- | ------- | ----- | ------- | ----- | ------ |
| 2015-2017   | -10.0%  | 70.1% | -34.0%  | -0.0  | 1.2    |
| 2016-2018   | 22.0%   | 80.0% | 6.0%    | 0.0   | 1.9    |
| 2017-2019   | 50.0%   | 80.0% | 28.0%   | 1.1   | 4.7    |
| 2018-2020   | 186.0%  | 80.5% | 163.0%  | 1.2   | 13.7   |
| 2019-2021   | 96.0%   | 80.5% | 49.0%   | 1.6   | 12.9   |
| 2020-2022   | -77.0%  | 80.5% | -76.0%  | 0.1   | 5.5    |
| 2021-2023   | -194.0% | 76.6% | -195.0% | -1.1  | 8.7    |
| 2022-2024   | 8.0%    | 76.6% | -13.0%  | -1.2  | 21.9   |
| 2023-2025   | 137.0%  | 76.6% | 74.0%   | 0.1   | 28.2   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate shows significant volatility, ranging from strongly negative (-194%) to very positive (186%). Recent periods (2023-2025) show strong growth.
*   **MDD:** Maximum Drawdown is consistently high, indicating significant risk and volatility.
*   **Alpha:** Alpha is also highly volatile, reflecting periods of significant outperformance and underperformance relative to the market.
*   **Beta:** Beta fluctuates around 1, indicating that NTRA's volatility is generally similar to the market, although there are periods where it deviates significantly.
*   **Cap(B):** Market capitalization has generally increased over time, suggesting growth in the company's overall size.

### 2. Recent Stock Price Movement

**Numbers:**

*   Current Price: 204.28
*   Previous Close: 200.67
*   Change: 1.8 (Implies a recent upward movement.)
*   5-day Moving Average: 205.56
*   20-day Moving Average: 197.18
*   60-day Moving Average: 178.91

**Analysis:**

The current price is slightly below the 5-day moving average but above the 20-day and 60-day moving averages. This suggests a short-term consolidation or slight pullback after a more extended upward trend. The 1.8 price change indicates a recent positive momentum, and this recent upward movement may contribute to short-term volatility.

### 3. Technical Indicators

**Numbers:**

*   Market Risk Indicator (MRI): 0.8 (Medium Investment Recommended)
*   RSI: 67.49 (Approaching overbought territory)
*   PPO: -0.11 (Slightly negative momentum)
*   Hybrid Signal: cash_0%_Buy 100% of cash (5 shares - Very Safe - MRI:0.90)
*   Recent (20-day) Relative Spread Change: 3.5 (+) (Short-term increase)
*   Expected Return: -84.3% (Long-term underperformance vs. S&P 500)

**Analysis:**

*   The MRI suggests a "Medium Investment Recommended" level of risk.
*   The RSI is approaching overbought territory, indicating a potential pullback soon.
*   The PPO indicates slightly negative momentum, contradicting the increase in spread change.
*   The Hybrid Signal suggests a strong buy signal with 100% cash allocation, based on safety and MRI, which contrasts the PPO and expected return data.
*   The positive change in the recent spread suggests short-term upward momentum relative to the S&P 500.
*   The significantly negative expected return suggests analysts anticipate Natera underperforming the S&P 500 over the long term.

### 4. Recent News & Significant Events

**Headlines:**

*   Liberty All-Star Growth Fund Update
*   Stanley Druckenmiller Exits Philip Morris
*   Does Natera Have a Long Runway For Growth?
*   Stocks That May Be Priced Below Intrinsic Value
*   Natera Integrates Oncology Tests With Flatiron Platform (x2)

**Analysis:**

*   The news headlines present a mixed picture. The integration with Flatiron Health's OncoEMR platform is a positive catalyst, suggesting expansion and improved market access for Natera's oncology tests.
*   The article about Natera's "long runway for growth" is also positive, suggesting confidence in the company's future prospects.
*   However, the news about Druckenmiller exiting Philip Morris and the Liberty All-Star Growth Fund update are not directly related to Natera. The news that Natera may be priced below intrinsic value is a positive sign but requires further investigation.

### 4-2. Analyst Opinions

**Numbers:**

*   Consensus: Strong Buy (~1.47)
*   Opinions: 19
*   Target Price (avg/high/low): 227.89 / 250.00 / 186.00

**Analysis:**

Analysts have a strong buy consensus on the stock, with an average target price of $227.89, suggesting potential upside from the current price of $204.28. However, it's essential to examine the reasoning behind these ratings and target prices.

### 5. Recent Earnings Analysis

| 날짜        | EPS     | 매출        |
| ----------- | ------- | ----------- |
| 2025-11-07  | -0.64   | 0.59 B$     |
| 2025-08-08  | -0.74   | 0.55 B$     |
| 2025-05-09  | -0.50   | 0.50 B$     |
| 2024-11-12  | -0.26   | 0.44 B$     |
| 2025-11-07  | -0.26   | 0.44 B$     |

**Analysis:**

*   Natera has consistently reported negative EPS, indicating ongoing losses.
*   Revenue has generally been increasing over the recent quarters, suggesting growth in the underlying business, but the company is not yet profitable.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
| ------------ | --------- | --------------- |
| 2025-09-30   | $0.59B    | 64.91%          |
| 2025-06-30   | $0.55B    | 63.41%          |
| 2025-03-31   | $0.50B    | 63.12%          |
| 2024-12-31   | $0.48B    | 62.94%          |
| 2024-09-30   | $0.44B    | 61.79%          |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
| ------------ | --------- | ------- |
| 2025-09-30   | $1.25B    | -6.99%  |
| 2025-06-30   | $1.25B    | -8.10%  |
| 2025-03-31   | $1.24B    | -5.40%  |
| 2024-12-31   | $1.20B    | -4.50%  |
| 2024-09-30   | $0.88B    | -3.60%  |

**Analysis:**

*   **Revenue:** Revenue shows a consistent upward trend, which is positive.
*   **Profit Margin:** Profit margins are high (60%+) and slightly increasing, indicating a strong ability to convert revenue into profit (before other expenses).
*   **Equity:** Equity is relatively stable, indicating a consistent capital base.
*   **ROE:** Return on Equity is negative, reflecting the company's unprofitability, although it is improving.

### 7. 종합적인 분석 (Overall Summary)

Natera Inc. (NTRA) presents a mixed investment picture:

**Positive Aspects:**

*   **Outperformance:** NTRA has outperformed the S&P 500 recently.
*   **Revenue Growth:**  The company is experiencing consistent revenue growth and has high and growing profit margins.
*   **Analyst Ratings:**  Strong Buy consensus from analysts with a potential upside based on target prices.
*   **Strategic Integrations:** The integration with Flatiron Health's OncoEMR platform is a positive development for market access.
*   **Market Risk Indicator:** MRI suggests a medium investment recommendation.

**Negative Aspects:**

*   **Unprofitability:** The company is consistently unprofitable (negative EPS and ROE).
*   **High Volatility:** The historical data shows significant volatility.
*   **Negative Expected Return:**  Analysts predict long-term underperformance compared to the S&P 500.
*   **RSI:** Is approaching overbought territory, indicating a potential pullback soon.

**Conclusion:**

Natera is a growth company with high potential but also significant risk. The integration with Flatiron Health and the positive revenue trend are encouraging signs. However, investors should be aware of the ongoing losses, high volatility, and analyst expectations of long-term underperformance relative to the S&P 500. The strong buy recommendations from analysts and the positive Hybrid Signal further complicates the overall assessment, indicating a divergence between quantitative and qualitative factors.
